NCT05877963Phase 3Recruiting

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

Study sponsor: TG Therapeutics, Inc. · TGTX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-01-21Estimated
Enrollment · participants800Estimated
Source updated2026-10-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: 1 Dec 2027. After: 21 Jan 2027.

Check registry source

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Part A: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab. After: Measure: Part A and Part C: Percentage of Participants With no Change or Reduction in Number of T1 Gd-Enhancing Lesions From Baseline to Week 48 Measure: Part B: Area Under the Curve Over the First 16 Weeks (AUC0-W16) of Ublituximab.

Primary completion date changed

Before: 1 Sep 2026. After: 1 Dec 2027.

Check registry source

· 2 fields changed

Planned enrollment increased by 200 participants

Before: 600 participants (planned). After: 800 participants (planned).

Primary completion date changed

Before: 1 Mar 2026. After: 1 Sep 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview